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Background: Hyponatremia is the most common electrolyte abnormality encountered in hospitalized patients,
resulting from a varied spectrum of conditions. Both the primary disturbance and its correction can result in
life-threatening neurological consequences. Extrapontine myelinolysis is one such complication that is associated
with the rapid correction of hyponatremia. Here we describe a patient who developed extrapontine myelinolysis
unexpectedly after the correction of hyponatremia, which involved the drug pituitrin.
Case presentation: A 24-year-old Chinese woman was transferred to our neurology department with the
symptoms of dysarthria and quadriparesis developing one day after the correction of hyponatremia (from
118 mmol/L to 140 mmol/L), which followed with a continuous intravenous drip of pituitrin used to control
hemoptysis in the emergency room. During the course, she developed involuntary movement. Magnetic resonance
imaging changes were consistent with extrapontine myelinolysis.
Conclusion: This present case describes the mechanism of profound hyponatremia involving pituitrin, and the
subsequent development of extrapontine myelinolysis. Physicians may approach effective clinical management of
patients through awareness of the adverse effect of pituitrin on serum sodium levels, and avoid rapid correction of
hyponatremia in clinical practice.
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Hemoptysis, a common symptom in clinical practice, can
sometimes become a life-threatening situation and require
urgent management. Pituitrin is the best available drug for
the control of severe pulmonary haemorrhage or repeated
hemoptysis due to its ability of strong vasoconstriction [1].
Untoward effects of pituitrin, such as hyponatremia, are
often ignored by physicians, as most patients with hypona-
tremia are asymptomatic. Hyponatremia is generally de-
fined as plasma sodium level of less than 135 mmol/L [2].
Although hyponatremia is a common and often underesti-
mated problem, rapid correction of chronic hyponatremia
can have devastating neurological consequences, i.e., cen-
tral pontine myelinolysis (CPM) and extrapontine myeli-
nolysis (EPM). CPM and EPM are two variants of osmotic
demyelination syndrome, which is related to rapid osmotic* Correspondence: tjqlyg@163.com; luobenyan@zju.edu.cn
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unless otherwise stated.changes, particularly an aggressive correction of hypona-
tremia [3]. EPM may involve the cerebellum, lateral gen-
iculate body, basal ganglia and cerebral white matter with
varied spectrum of symptoms. Parkinsonism is common,
while involuntary movements such as dystonia and myo-
clonus are less frequently observed [3,4]. We report a case
of iatrogenic EPM presenting with dysarthria, quadripar-
esis and involuntary movements following correction of
hyponatremia associated with pituitrin.
Case presentation
A 24-year-old Chinese woman was transferred to our neur-
ology department presenting with dysarthria and quadri-
paresis. The patient had a medical history of tetralogy of
Fallot since infancy with resulting cyanosis. Corrective sur-
gery was undertaken 4 years ago, and she had been stable
and functionally well since then. She had no other comor-
bid conditions such as alcoholism, malnutrition, hepatic
cirrhosis or renal insufficiency. The episode began when
the patient contracted repeated minor hemoptysis, she re-
ceived conventional therapy with aminomethylbenzoic acidl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Changes of the patient’s serum sodium concentration.
Triangles showing the serum sodium gradually decreased with the
use of pituitrin, the black arrow pointing out the day beginning use
of hypertonic saline.
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began to get a fever and was transferred to the emergency
room in our hospital.
On admission, her symptoms worsened with a massive
hemoptysis, and pituitrin was prescribed to control the
bleeding. Further assessment of the origin of bleeding
by computed tomography (CT) angiography of the chest
showed that the right bronchial artery was slightly di-
lated, and a multidisciplinary consultation suggested ex-
pectant treatment with pituitrin instead of bronchial
artery embolization. Pituitrin (18 U in 30 ml of saline) was
administered by intravenous drip continuously at a rate of
2 ~ 3 ml/h via a pump for six days. On the fourth admission
day, the patient became nauseous and exhibited generalized
weakness. Blood tests revealed a profound hyponatremia
with a sodium level of 118 mmol/L, a serum osmolality of
253 mOsm/kg H2O, and hepatic and renal functions were
normal. Other biochemical tests showed normal thyroid
function, and serum cortisol and adrenocorticotropic hor-
mone were within the normal range. The patient was resus-
citated with i.v. hypertonic saline, and the sodium level was
140 mmol/L four days later (Figure 1). Unfortunately, the
next day she deteriorated once more, initially developing
dysarthria and quadriparesis. An immediate CT of the headFigure 2 Brain magnetic resonance imaging. A, axial T1-weighted MRI s
B, axial T2-weighted MRI showing high signal intensity of bilateral symmet
pons (the red arrows pointing out the lesions).presented normal, and she was transferred to our neurology
department. During the course, she developed involuntary
movements, mainly paroxysmal oromandibular dystonia
and myoclonus in the left upper limb. Magnetic resonance
imaging (MRI) showed bilateral symmetric basal ganglia
lesions consistent with EPM (Figure 2). She was treated
mainly with corticosteroid, diazepam and hyperbaric oxy-
gen therapy and was discharged with few residual symp-
toms (speaking with relative fluency and walking on her
own without involuntary movements).
Conclusions
This patient developed EPM unexpectedly after the intra-
venous use of pituitrin to control hemoptysis. Pituitrin,
extracted from the posterior pituitary, consists of oxytocin
and vasopressin. The latter can activate type-1A receptors
located in vascular smooth muscle cells resulting in vaso-
constriction [5]. Thus, pituitrin has been used in gastro-
intestinal or pulmonary haemorrhage, and the result is
almost as if forceps had been applied directly to the bleed-
ing vessel. In addition, water reabsorption is mediated by
vasopressin activation of type-2 receptors in the basolat-
eral membrane of cells in the renal collecting ducts, which
causes a decrease in plasma osmolality [5]. There was no
medical history of hyponatremia, absence of adrenal, thy-
roid, pituitary or renal insufficiency, and no recent use of
diuretic agents in this patient; pituitrin was implicated as
the very probable contributory factor to the development
of severe hyponatremia.
Hyponatremia can be classified into acute (<48 h) and
chronic (≥48 h) hyponatremia. When hyponatremia de-
velops, the brain reduces the number of osmotically ac-
tive particles within its cells (mostly organic solutes) in
an attempt to adapt to the osmotic change, which takes
48 h [6]. CPM and EPM are acquired metabolic disor-
ders of acute central demyelination strongly associated
with rapid correction of hyponatremia [7]. CPM typicallyhowing low signal intensity of bilateral symmetric basal ganglia;
ric basal ganglia; C, axial T2-weighted MRI showing no lesion in the
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brain regions, such as the cerebellum, thalamus, basal
ganglia or subcortical white matter. Clinical heterogen-
eity due to CPM/EPM affecting the basal ganglia has
been reviewed by de Souza A [8], such as dystonia, tremor,
myoclonus, gait disorders, dysarthria, cognitive impair-
ment, depression and others. Focal oromandibular dys-
tonia and asymmetric myoclonus that developed in a
delayed manner in the patient are rare presentations. The
possibility that delayed movement disorders may arise in
EPM due to ineffective or faulty reorganization in the
basal ganglia has been considered in an earlier report [9].
Sequential observation of symptoms and brain images in
the case of CPM and EPM revealed that delayed move-
ment disorders as a result of changes in the signal of the
basal ganglia, were explained by the destruction of re-
gional myelin [10]. Special populations seem vulnerable to
the development of osmotic myelinolysis, including not
only alcoholics and malnourished patients but also those
with liver disease, sepsis, adrenal insufficiency and severe
burns [11]. Previous cases have shown that the chronicity
of hyponatremia before correction is a critical risk factor
for the development of osmotic myelinolysis [12,13]. In
this patient, chronic hyponatremia was documented to
exist for at least 48 h, and after a rapid increase of serum
sodium from 118 mmol/L to 134 mmol/L in 24 h, there
was a delay of one day before progressive neurological de-
cline. Recommendations suggest that ideally hyponatremia
should be corrected by limiting the sodium increase to
not more than 8–10 mmol/L every 24 h [2]. We identified
three cases, each reporting a single case in which deamino
arginine vasopressin, a type of vasopressin analogue, was
implicated as a possible contributory factor to the devel-
opment of severe electrolyte imbalances that triggered
osmotic demyelination [14-16]. Although the true aeti-
ology of CPM/EPM remains unclear, abrupt osmotic
shifts have been considered to play a critical role in their
pathogenesis. Deamino arginine vasopressin and pitui-
trin may predispose patients to osmotic demyelination
by causing hyponatremia and extreme serum sodium
fluctuations rather than by exerting any direct myelino-
lytic effect. Further studies are needed to clarify whether
the use of pituitrin or its analogue is associated with a
risk of osmotic demyelination independent of the elec-
trolyte disturbance.
This case and literature review highlight that: 1) Hypona-
tremia is the most frequent electrolyte disturbance ob-
served in hospitalized patients [17]. Drugs such as pituitrin
can cause profound hyponatremia, which should be con-
sidered in the differential diagnosis when approaching a
patient with hyponatremia. 2) Osmotic myelinolysis is
most frequently associated with rapid correction of hypo-
natremia [3]. Prevention of CPM and EPM by exercising
caution in the correction of hyponatremia, especiallychronic hyponatremia, is more important than early
diagnosis.
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